Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics

Xeris Pharmaceuticals has a market cap or net worth of $877.65M. The enterprise value is $1.05B.

Xeris Pharmaceuticals has 160,155,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xeris Pharmaceuticals’s return on equity (ROE) is 1.85 and return on invested capital (ROIC) is -12.93%.

The current PE Ratio of Xeris Pharmaceuticals is ―. Xeris Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Xeris Pharmaceuticals had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.

In the last 12 months, operating cash flow was -26.71M and capital expenditures -717.00K, giving a free cash flow of -27.43M billion.

Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Xeris Pharmaceuticals upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).

Xeris Pharmaceuticals as a current ratio of 1.67, with Debt / Equity ratio of -765.06%

In the past 12 months, Xeris Pharmaceuticals has paid -2.27M in taxes.

Xeris Pharmaceuticals EV to EBITDA ratio is -61.69, with an EV/FCF ratio of -18.43.

Xeris Pharmaceuticals has $58.44M in cash and marketable securities with $268.75M in debt, giving a net cash position of $210.31M billion.

Gross margin is 80.99%, with operating margin of -16.57%, and net profit margin of -27.00%.

The average price target for Xeris Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy